

**Table S4. Estimated excess number of bed-days and costs associated with methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) *S. aureus* and third-generation cephalosporin-resistant (G3CREC) and third-generation cephalosporin-susceptible (G3CSEC) *E. coli* bacteremias in 2007.**

Country	Excess number of bed-days in thousands (CI <sub>95</sub> )				Excess costs in thousand Euros (CI <sub>95</sub> )			
	MRSA	MSSA	G3CREC	G3CSEC	MRSA	MSSA	G3CREC	G3CSEC
Austria	1.2 (0.7-1.8)	11.6 (9.2-14.1)	1.8 (0.8-3.0)	6.6 (4.0-9.2)	279 (157-413)	2630 (2092-3192)	407 (180-674)	1492 (909-2083)
Belgium	2.3 (1.2-3.6)	7.2 (5.5-8.9)	0.7 (0.3-1.2)	5.7 (3.5-8.0)	506 (273-787)	1575 (1218-1967)	147 (59-269)	1255 (762-1764)
Bulgaria	0.6 (0.3-1.1)	3.9 (2.9-5.1)	1.1 (0.5-2.0)	1.3 (0.8-1.9)	20 (9-37)	127 (94-165)	36 (15-65)	42 (25-62)
Croatia	2.0 (1.1-3.0)	3.0 (2.4-3.7)	0.3 (0.1-0.5)	3.5 (2.2-4.9)	136 (76-204)	207 (163-254)	21 (9-36)	243 (148-340)
Cyprus	0.8 (0.4-1.3)	0.8 (0.6-1.1)	0.4 (0.1-0.6)	0.5 (0.3-0.8)	119 (64-185)	118 (87-156)	52 (22-94)	79 (47-115)
Czech Rep.	2.3 (1.3-3.5)	14.5 (11.6-17.6)	1.6 (0.7-2.6)	7.5 (4.6-10.5)	214 (120-319)	1329 (1060-1612)	143 (63-237)	690 (420-963)
Denmark	0.2 (0.1-0.5)	13.2 (10.3-16.4)	0.6 (0.2-1.3)	7.4 (4.5-10.5)	55 (15-143)	3745 (2906-4642)	182 (69-354)	2108 (1283-2978)
Estonia <sup>a</sup>	0.2 (0.1-0.2)	1.6 (1.3-2.0)	0.0	0.6 (0.4-0.9)	13 (8-20)	130 (103-158)	1 (1-2)	50 (31-70)
Finland	0.1 (0.0-0.2)	4.9 (3.9-6.1)	0.3 (0.1-0.5)	4.5 (2.8-6.3)	27 (12-50)	1144 (901-1407)	59 (24-107)	1048 (643-1470)
France	41.7 (23.3-62)	110.2 (87.6-134.0)	4.9 (2.1-8.3)	86.3 (52.6-120.3)	8941 (4999-13,281)	23,600 (18,757-28,711)	1045 (450-1788)	18,489 (11,269-25,776)
Germany	22.9 (10.1-42.6)	105.4 (75.6-141.7)	15.2 (5.3-32.4)	62.2 (36.8-90.8)	4878 (2144-9077)	22,447 (16,093-30,167)	3239 (1118-6890)	13,238 (7840-19,337)
Greece	11.1 (5.8-18.0)	11.4 (7.7-16.1)	0.9 (0.2-2.5)	3.6 (2.0-5.7)	1850 (967-2998)	1900 (1287-2679)	145 (32-422)	606 (340-940)
Hungary <sup>a</sup>	2.6 (1.5-3.8)	7.9 (6.3-9.6)	0.5 (0.2-0.8)	3.2 (2.0-4.5)	218 (123-322)	666 (530-809)	39 (17-65)	272 (166-380)

Country	Excess number of bed-days in thousands (CI <sub>95</sub> )				Excess costs in thousand Euros (CI <sub>95</sub> )			
	MRSA	MSSA	G3CREC	G3CSEC	MRSA	MSSA	G3CREC	G3CSEC
Iceland <sup>a</sup>	0.0	0.6 (0.4-0.7)	0.0 (0.0-0.1)	0.3 (0.2-0.4)	0	164 (131-199)	9 (4-15)	86 (52-120)
Ireland <sup>a</sup>	4.7 (2.6-6.9)	7.1 (5.6-8.6)	0.7 (0.3-1.2)	4.8 (2.9-6.7)	1367 (770-2023)	2065 (1642-2507)	203 (90-337)	1397 (851-1949)
Israel	5.3 (2.9-7.9)	10.0 (7.8-12.3)	4.4 (1.9-7.4)	9.8 (6.0-13.8)	662 (367-991)	1252 (977-1545)	553 (240-930)	1228 (751-1721)
Italy	24.7 (13.7-37.2)	44.4 (34.5-55.0)	9.1 (3.9-15.6)	26.6 (16.1-37.5)	4811 (2670-7252)	8635 (6718-10,711)	1770 (758-3046)	5183 (3132-7310)
Latvia	0.3 (0.1-0.4)	2.7 (2.1-3.3)	0.2 (0.1-0.3)	0.4 (0.2-0.5)	16 (8-27)	162 (127-203)	11 (4-21)	23 (14-33)
Lithuania	0.3 (0.2-0.5)	3 (2.4-3.7)	0.2 (0.1-0.4)	1.0 (0.6-1.4)	19 (10-32)	180 (141-224)	13 (5-24)	61 (37-86)
Luxembourg <sup>a</sup>	0.2 (0.1-0.3)	0.8 (0.6-0.9)	0.1 (0.0-0.1)	0.8 (0.5-1.1)	93 (52-138)	328 (261-398)	37 (16-61)	319 (194-445)
Malta <sup>a</sup>	0.5 (0.3-0.8)	0.4 (0.3-0.5)	0.1 (0.1-0.2)	0.3 (0.2-0.4)	51 (29-76)	43 (34-53)	12 (5-20)	30 (18-41)
Netherlands	0.3 (0.1-0.9)	25.6 (20.0-31.6)	1.6 (0.6-3.0)	13.6 (8.2-19.1)	78 (21-208)	5971 (4662-7390)	378 (150-711)	3177 (1923-4467)
Norway	0	11.0 (8.6-13.5)	0.5 (0.2-0.9)	8.1 (4.9-11.3)	0	3865 (3033-4758)	164 (65-306)	2850 (1736-3996)
Poland	3.0 (1.5-4.9)	15.2 (11.6-19.5)	0.5 (0.1-1.2)	8 (4.8-11.4)	195 (98-322)	998 (758-1277)	33 (9-81)	523 (317-747)
Portugal	18.4 (10.3-27.3)	18.5 (14.6-22.6)	3.4 (1.5-5.7)	11.1 (6.7-15.5)	2276 (1277-3383)	2294 (1812-2803)	423 (186-712)	1378 (837-1922)
Romania	1.3 (0.6-2.5)	3.3 (2.1-4.8)	1.8 (0.7-3.4)	1.6 (0.9-2.4)	57 (25-110)	146 (96-213)	79 (30-151)	71 (40-107)
Slovenia <sup>a</sup>	0.3 (0.2-0.5)	3.4 (2.7-4.1)	0.3 (0.1-0.5)	2.4 (1.5-3.3)	31 (17-46)	319 (254-387)	26 (12-43)	226 (138-315)
Spain	20.5 (11.4-30.8)	57.1 (45.1-70.0)	10.9 (4.8-18.5)	52.9 (32.3-73.9)	3529 (1964-5299)	9816 (7749-12,030)	1882 (825-3186)	9097 (5553-12,704)

Country	Excess number of bed-days in thousands (CI <sub>95</sub> )				Excess costs in thousand Euros (CI <sub>95</sub> )			
	MRSA	MSSA	G3CREC	G3CSEC	MRSA	MSSA	G3CREC	G3CSEC
Sweden	0.2 (0.1-0.4)	21.7 (17.3-26.3)	0.7 (0.3-1.2)	12.6 (7.7-17.6)	58 (32-90)	5432 (4323-6588)	178 (79-297)	3152 (1923-4398)
Turkey	36.6 (20.5-55)	65.8 (52.0-80.5)	35.1 (15.4-59.0)	19.2 (11.6-27.0)	1705 (956-2560)	3061 (2420-3748)	1634 (719-2747)	892 (540-1259)
UK <sup>a</sup>	50.9 (28.7-75.4)	105.5 (83.9-128.1)	22.3 (9.9-36.9)	59.7 (36.4-83.3)	11,755 (6622-17,393)	24,350 (19,362-29,557)	5147 (2279-8525)	13,782 (8398-19,233)
<b>Total</b>	255.7 (142.9-375.9)	691.4 (548.5-840)	120.1 (52.3-198.3)	426.2 (259.6-594.9)	43,961 (23,885-67,786)	128,701 (99,791-160,510)	18,068 (7535-32,216)	83,087 (50,337-117,131)

Countries include all European Union member states (excluding Slovakia), both candidate countries (Croatia and Turkey), two EFTA countries (Iceland and Norway), and Israel.

<sup>a</sup>Total number as reported to EARSS or by national health authorities (UK), CI solely based on CI of the excess length of stay estimate from the clinical outcome studies; CI<sub>95</sub>= 95% confidence interval; Rep. = Republic